Main textEngineering biology with recombinant DNA, broadly called synthetic biology, is a growing economic force. As of 2018, 98 companies raised 3.8 billion dollars ( 1 ) to catalyze the development of customized biological solutions for therapeutics, agriculture, energy and materials.Synthetic biology has progressed tremendously in the last decade, owing to continued industrialization of DNA synthesis, discovery and development of molecular tools and organisms, as well as increasingly more sophisticated modeling and analytic software tools. However, we have yet to understand the full potential of engineering biology due to our inability to write and test whole genomes, which we call synthetic genomics.